Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06690957
Recruiting Observational

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients

NCT06690957 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University
Phase
Observational
Started
2019-02-01
Last updated
2026-09-08

Condition(s) studied

SSTR-related DiseaseTumorPositron Emission TomographyMetastasis

Investigational drug(s) / intervention(s)

68Ga/18F-TATE/JR11/LM3

68Ga/18F-TATE/JR11/LM3: Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.

Study summary

To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Primary outcome measure(s)

  • Standardized uptake value (SUV) — 30 days
    Standardized uptake value (SUV) of tracers for each target lesion of subject or suspected primary tumor or/and metastasis.

Trial sites (3)

FacilityCityRegionStatus
The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui Recruiting
The Affiliated Hospital of Qingdao University Qingdao Shandong Recruiting
Tianjin Medical University General Hospital Tianjin Tianjin Municipality Recruiting

More Tianjin Medical University trials in China

SNRK & Vascular Endothelial Aging Recruiting
ALI & Pulmonary HA Deposition After SAH Recruiting
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease Recruiting
Beta Amyloid PET/CT in Various Aβ-Related Disease Recruiting
Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD Starting soon

Other trials for the same condition

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC Starting soon
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases Recruiting
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer Recruiting
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor Active, not recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06690957 on ClinicalTrials.gov ↗ ← All trials in China